Healthier populations, everywhere

MMGH is part of the Vaccine Against Invasive non-typhoidal Salmonella (Vacc-iNTS) consortium, made up of 12 partners from eight different countries including three disease-endemic countries. The initiative advances the development of an iNTS vaccine by conducting a Phase I clinical study in Europe and Africa. The project, funded by the European Union’s Horizon 2020 Research and Innovation Programme, will investigate the immunogenicity and safety of a iNTS-GMMA vaccine. As part of this effort MMGH will focus on strengthening a collaborative network to enhance disease awareness and drive vaccine advocacy.

Assess global supply, demand and price dynamics for key vaccine markets and advise on how to best address constraints to safe, effective, quality and affordable vaccines for all. 

Establishing the business case for investment in new drugs to treat the neglected tropical diseases onchocerciasis and lymphatic filariasis.

MMGH supported the WHO Initiative for Vaccine Research (IVR) in updating the Preferred Product Characteristics for the Oral Cholera Vaccine. MMGH facilitated the expert meeting and coordinated the drafting of the final document providing updated guidance to vaccine developers consistent with the strategic axes of the new Cholera Roadmap.

Development of a business case for investment and further development of a schistosomiasis vaccine.

Develop a multi-sectorial investment case to support advocacy for fundraising to implement the Ending Cholera: A Global Roadmap to 2030 strategy.

Create a product development plan and financial analysis to translate scientific discoveries and early clinical development into public health interventions to help control leishmaniasis.

MMGH supported the WHO Initiative for Vaccine Research (IVR) in preparing a report on the considerations for operationalising group B streptococcal (GBS) maternal vaccination as part of a Public Health Value Proposition for GBS vaccines. The report was developed on the basis of an extensive literature review and an online survey gathering information on global and country stakeholder perceptions on GBS disease, its public health importance, and the prioritisation of GBS vaccination as a means to reduce its impact.

Development of a business case for the use of macrofilaricide drugs to control onchocerciasis.

MMGH supported the WHO Initiative for Vaccine Research (IVR) in developing a variety of forecast scenarios for the demand of a group B streptococcal (GBS) vaccine administered through maternal immunisation. The forecast was validated by an Expert Advisory Group. Based on the potential vaccine profiles, MMGH assessed the financial viability of the vaccine for a prospective developer. The output of the work will inform the WHO Public Health Value Proposition and contribute to advocacy efforts aimed at supporting the creation of a healthy market for the vaccine.

Development of the European regional adaptation of the global vision and strategies for immunization for the period 2021-2030.

Testing regional self-sufficiency for access to the COVID-19 vaccine in Asia. 

Evaluate the viability and impact of investment in the clinical development of a new TB vaccine.

Develop and validate use cases for typhoid conjugate vaccine microarray patches (TCV-MAPs), determine which countries would use TCV-MAPs, and forecast potential demand as part of the development of the full vaccine value assessment.

MMGH supports the WHO’s Vaccine Product & Delivery Research department in defining and sizing (including a demand forecast) the use cases for a Measles Rubella vaccine micro-array patch (MAP). The use cases and their market sises are assessed and validated via expert consultation across a broad group of stakeholders, including country programme managers, global experts, and pharmaceutical and development agencies. The approach and methodology was validated by the WHO Immunisation and Vaccines Related Implementation Research Advisory Committee (IVIR-AC), Measles-Rubella MR-MAP Working group, and the Market for Information to Access Advisory Group. The project is now focusing on further understanding self-administration of MR-MAPs and will be extended to include MMR-MAPs. The project will help the WHO in better aligning MAP product development efforts to the measles-rubella control and implementation needs and the Gavi Vaccine Innovation Prioritisation Strategy (VIPS).